Dr. David R. Lynch
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Neurology
Philadelphia, PA 19104
- Medicare participating
At a glance
- Medical school
- Johns Hopkins University School of Medicine (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 28
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: Johns Hopkins University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
PA license MD042717L -
Pediatrics Physician
PA license MD042717L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Childrens Health Care Associates Inc (220 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 28
- Services billed
- 34
- Patients’ average age
- 45
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 32 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Skyclarys (omaveloxolone) | 337 |
| Baclofen Other prescribers in Philadelphia, PA | 128 |
| Gabapentin Other prescribers in Philadelphia, PA | 82 |
| Amantadine (amantadine hcl) Other prescribers in Philadelphia, PA | 47 |
| Citalopram Hbr (citalopram hydrobromide) Other prescribers in Philadelphia, PA | 32 |
| Levetiracetam Other prescribers in Philadelphia, PA | 19 |
| Levocarnitine | 15 |
| Oxybutynin Chloride Er (oxybutynin chloride) Other prescribers in Philadelphia, PA | 13 |
| Primidone Other prescribers in Philadelphia, PA | 13 |
| Riluzole | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 11 payments worth $9,704 in total to this clinician.
| Biogen, Inc. | $9,576 |
|---|---|
| Ptc Therapeutics, Inc. | $128 |
| Consulting Fee | $8,220 |
|---|---|
| Travel and Lodging | $1,042 |
| Food and Beverage | $443 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Biogen, Inc. Jun 12, 2025 | Consulting Fee | $8,220 |
| Biogen, Inc. Aug 14, 2025 | Travel and Lodging SKYCLARYS · Neurology · travel to Atlanta, GA · in-kind | $499 |
| Biogen, Inc. Aug 14, 2025 | Travel and Lodging SKYCLARYS · Neurology · travel to Atlanta, GA · in-kind | $324 |
| Biogen, Inc. Aug 14, 2025 | Travel and Lodging SKYCLARYS · Neurology · travel to Atlanta, GA · in-kind | $163 |
| Biogen, Inc. Aug 15, 2025 | Travel and Lodging SKYCLARYS · Neurology · travel to Atlanta, GA | $56.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 3 companies. The companies reported $1,137,093 in research payments for these studies, mostly to the institutions running them.
- A Study of Omaveloxolone in Children With Friedreich's Ataxia (BOLD)
Biogen, Inc. - A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
Biogen, Inc. - A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
Ptc Therapeutics, Inc. · Active, not recruiting · NCT05515536 - A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
Ptc Therapeutics, Inc. · Completed · NCT05218655 - A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it for the First Time
Biogen, Inc. - RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe
Biogen, Inc. - An Evaluation of the Pharmacokinetics and Safety of a Single Dose of Ralinepag in Participants with Renal Impairment
United Therapeutics Corporation - A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
Ptc Therapeutics, Inc. · Completed · NCT05485987
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.